3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
CNS
2
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
100
Nivolumab
69
Cyclophosphamide
67
Ipilimumab
66
fludarabine
34
aldesleukin
29
fludarabine phosphate
28
Vemurafenib
28
Interleukin-2
26
trametinib
20
Biopsy
20
dabrafenib
17
Radiotherapy
16
Temozolomide
15
Cisplatin
15
Magnetic Resonance Spectroscopy
14
Gemcitabine
14
Filgrastim
14
atezolizumab
13
Carboplatin
13
CTLA-4 Antigen
13
spartalizumab
12
romidepsin
12
Specimen Handling
12
Paclitaxel
12
Bortezomib
11
poly ICLC
10
cobimetinib
10
Peripheral Blood Stem Cell Transplantation
10
Oxaliplatin
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
1-methyltryptophan
×
Dermatologic
×
Clear all
NCT00739609
2020-05-28
D-1MT
Lumos Pharma
Phase 1
Terminated
17 enrolled